Evidence map›Paper›PMID 38660635›Full record

ReviewWorld journal of gastrointestinal oncology2024

Colorectal cancer screening: A review of current knowledge and progress in research.

Sara Ramos Lopes, Claudio Martins, Inês Costa Santos, Madalena Teixeira, Élia Gamito, Ana Luisa Alves

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. TruncatingJournal of cancer prevention · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Molecular therapy. Oncology · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sara Ramos LopesDepartment of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal 2910-446, Portugal.
Claudio MartinsDepartment of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt.
Inês Costa SantosDepartment of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal 2910-446, Portugal.
Madalena TeixeiraDepartment of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal 2910-446, Portugal.
Élia GamitoDepartment of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal 2910-446, Portugal.
Ana Luisa AlvesDepartment of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal 2910-446, Portugal.
Hospital de São Bernardo · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, being the third most commonly diagnosed malignancy and the second leading cause of cancer-related deaths globally. Despite the progress in screening, early diagnosis, and treatment, approximately 20%-25% of CRC patients still present with metastatic disease at the time of their initial diagnosis. Furthermore, the burden of disease is still expected to increase, especially in individuals younger than 50 years old, among whom early-onset CRC incidence has been increasing. Screening and early detection are pivotal to improve CRC-related outcomes. It is well established that CRC screening not only reduces incidence, but also decreases deaths from CRC. Diverse screening strategies have proven effective in decreasing both CRC incidence and mortality, though variations in efficacy have been reported across the literature. However, uncertainties persist regarding the optimal screening method, age intervals and periodicity. Moreover, adherence to CRC screening remains globally low. In recent years, emerging technologies, notably artificial intelligence, and non-invasive biomarkers, have been developed to overcome these barriers. However, controversy exists over the actual impact of some of the new discoveries on CRC-related outcomes and how to effectively integrate them into daily practice. In this review, we aim to cover the current evidence surrounding CRC screening. We will further critically assess novel approaches under investigation, in an effort to differentiate promising innovations from mere novelties.

Indexed as

Artificial intelligenceColorectal cancerOncologyReviewScreening

Identifiers

PMID38660635
PMCPMC11037045
OpenAlexW4394633398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.